A biotech company, founded by researchers from the University of Munich, has developed a fascinating way to make the immune system fight cancer.
On Thursday, Micromet Inc. announced that its experimental drug, MT103, had impressive results in a test upon seven Non-Hodgkin's Lymphoma patients. All of them had failed at least three conventional treatments, but showed signs of recovery after receiving doses of a two-headed antibody. (Full Story at wired)
|